News | Implantable Cardioverter Defibrillator (ICD) | January 18, 2017

New Study Highlights Benefit of ICDs for Non-ischemic Cardiomyopathy Patients

University of Alabama at Birmingham research team finds employing implantable cardioverter-defibrillators reduces all-cause mortality 23 percent in patient group

ICDs, non-ischemic cardiomyopathy, University of Alabama at Birmingham study, Circulation

January 18, 2017 — A new study published in Circulation has found there is a 23 percent risk in reduction of all-cause mortality in non-ischemic cardiomyopathy patients with use of implantable cardioverter-defibrillator (ICD) therapy.

A team of researchers from the University of Alabama at Birmingham (UAB) identified six clinical trials with 2,970 patients with non-ischemic cardiomyopathy to study the efficacy of ICD for primary prevention. Investigators reported data on all-cause mortality from these clinical trials.

An ICD is a small device that is placed in the chest or abdomen. Doctors use the device to help treat irregular heartbeats, called arrhythmias.

“While the data supporting the use of ICDs is robust in patients with ischemic cardiomyopathy, limited clinical trial data existed for similar benefit in patients with non-ischemic cardiomyopathy,” said senior author Pankaj Arora, M.D., assistant professor in the Division of Cardiovascular Disease.

Researchers found that, despite the neutral results of the recently published DANISH trial, the current analyses demonstrated significant clinical benefit on all-cause mortality in favor of ICD use for primary prevention in patients with non-ischemic cardiomyopathy. Additional UAB co-authors of the Circulation manuscript are Navkaranbir Singh Bajaj, M.D., and Garima Arora, M.D., in the Division of Cardiovascular Disease.

“Traditional reliance on ejection fraction — which is the percentage of blood that is ejected out of the ventricles with each contraction — for risk stratification of sudden cardiac death is not an ideal approach,” he said.

Arora noted that, in the future, improvement in risk-prediction models to provide personalized decisions on who should get an ICD hopefully will become standard of care. Until then, the authors concluded that clinical judgment should prevail while assessing risk of sudden cardiac in non-ischemic cardiomyopathy patients with reduced ejection fraction.

For more information: www.circ.ahajournals.org

References

Golwala, H., Bajaj, N.S., Arora, G., Arora, P. "Implantable Cardioverter-Defibrillator for Nonischemic Cardiomyopathy: An Updated Meta-Analysis," Circulation. Published Dec. 19, 2016. https://doi.org/10.1161/CIRCULATIONAHA.116.026056

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init